Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes

Diabetologia

Volumn 48, Issue 4, 2005, Pages 616-620

  Mest, H J ^a   Mentlein, R ^b  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Dipeptidyl peptidase IV; Glucagon like peptide 1; Incretin; Inhibitor; Insulinotropic effect; Novel drug; Side effect; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROPEPTIDE; PEPTIDE HORMONE; PROTEINASE;

ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLAMMATION; INSULIN LIKE ACTIVITY; INSULIN RELEASE; NAUSEA AND VOMITING; NEUROGENIC INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; RISK ASSESSMENT; SIDE EFFECT; SPLENOMEGALY; STOMACH EMPTYING; THROMBOCYTOPENIA;

ADENOSINE DEAMINASE; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLYCOPROTEINS; HUMANS; INSULIN; MODELS, BIOLOGICAL; NERVE GROWTH FACTORS; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; PEPTIDE FRAGMENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN PRECURSORS; TIME FACTORS;

EID: 17844362518     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1707-5     Document Type: Article

References (20)

1. Mentlein R (2005) Therapeutic assessment of GLP-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential anti-diabetic drugs. Expert Opin Investig Drugs 14:57-64
2. Ahrén B, Simonsson E, Larsson H et al (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875
3. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A (2004) Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880
4. Brenner MB, Gromada L, Efanov AM, Bokvist K, Mest H-J (2003) Restoration of first-phase insulin secretion by the imidazoline compound LY374284 in pancreatic islets of diabetes db/db mice. Ann NY Acad Sci 1009:332-340
5. Ahrén B, Hughes TE (2004) Inhibition of DPP-4 augments insulin secretion in response to exogenously administered GLP-1, GIP, PACAP and GRP in mice. Endocrinology (in press)
6. Conarello SL, Li Z, Ronan J et al (2003) Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A 100:6825-6830
7. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613
8. Holst JJ, Deacon CF (2005) Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia DOI 10.1007/s00125-005- 1705-7
9. Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596
10. Knudsen LB, Pridal L (1996) Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-3 6) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429-435
11. Gault VA, Parker JC, Harriott P, Flatt PR, O'Harte FP (2002) Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 175:525-533
12. Ludwig A, Schiemann F, Mentlein R, Lindner B, Brandt E (2002) Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J Leukoc Biol 72:183-191
13. Proost P, Schutyser E, Menten P et al (2001) Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 98:3554-3561
14. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU (1998) Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47:1253-1258
15. Pospisilik JA, Stafford SG, Demuth HU et al (2002) Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51:943-950
16. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regulatory Pept 85:9-24
17. Mentlein R (2004) Cell surface peptidases. Int Rev Cyt 235:165-213
18. Rosenblum JS, Kozarich JW (2003) Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 7:496-504
19. Lankas G, Leiting B, Roy RS et al (2004) Inhibition of DPP8/9 results in toxicity in preclinical studies: potential importance of selective dipeptidyl peptidase IV inhibition for the treatment of type 2 DM. Diabetes 53(Suppl 2):A2
20. Degn KB, Brock B, Juhl CB et al (2004) Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycaemia. Diabetes 53:2397-2403